Kolinpharma
Ethica Group alongside Hyle Capital Partners SGR in the voluntary takeover bid for Kolinpharma
Ethica Group, with the M&A Advisory and Debt Advisory teams, assisted Igea Holding, a vehicle controlled by Hyle Capital Partners, in the voluntary takeover bid for Kolinpharma, a leading Italian company in nutraceuticals.
Founded in 2013, Kolinpharma was listed on the Euronext Growth Milan multilateral trading system since 2018. The company specializes in the research and development of nutraceutical products to support pharmacological treatments for pathologies in orthopedics-physiatry and urology-gynecology. Kolinpharma’s products also stand out for their marked innovation and attention to environmental and ESG policies.